Skip to content

    Cancer

    IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases

    Spine Institute

    What is the purpose of this study?

    The purpose of the study is to determine the recurrence rates and survival of patients with clinical T1-2N0 ER+/Her2- invasive breast cancer who have biopsy proven image detected nodal disease treated with upfront lumpectomy or mastectomy with TAD followed by adjuvant therapy. This is a prospective, single arm phase II clinical trial. Patients will be screened and enrolled per eligibility criteria. Patient, tumor, and treatment data will be documented.

    Eligibility

    • Women age ≥ 45
    • Clinical T1-2N0 ER+ invasive breast cancer
    • US detected biopsy proven axillary nodal disease
    • Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.

    Where can I participate?

    Hoag Hospital - Newport Beach
    1 Hoag Dr
    Newport Beach, CA 92663


    Bob Doe

    firstName.lastName@hoag.org


    Hoag Hospital — Irvine

    16200 Sand Canyon Ave
    Irvine, CA 92618


    John Doe

    john.doe@hoag.org


    More about this Clinical Trial

    What is the full name of this Clinical Trial?

    IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Clinical T1-2N0 ER+ Her2- Breast Cancer With Ultrasound Detected Nodal Metastases

    • Disease Type/ConditionBreast Cancer With Nodal Metastases
    • Principal InvestigatorBob Jameson
    • Co-InvestigatorsSarah Towns, Clark Kent
    • Age GroupAdult, Older Adult
    • PhaseII
    • IRB NumberSTUDY06092892
    • ClinicalTrials.gov IDNCT06092892

    Digestive Health Institute

    As a national leader in digestive care and the top-ranked Gastroenterology and GI Surgery center in OC, Hoag provides expert care across the full spectrum of digestive disease. Patients have access to a host of groundbreaking technologies, world-class specialists, clinical trials, diagnostics & imaging, and advanced interventional therapeutics.
    Hantavirus headlines are back: What you need to know

    More Digestive
Health Trials

    See All

    Stay up-to-date on the latest news from Hoag

    By submitting this request, you agree to receive communications from Hoag and accept our Privacy Policy and Terms of Use.